Differential impact of Lewy body disease and Alzheimer’s disease neuropathology on cognition
Objective: To examine the impact of Lewy body disease neuropathology (LBD) on domain-specific cognitive impairment in isolation and in combination with Alzheimer’s disease neuropathologic change…Alpha-synuclein DNA methylation in CD45+ blood cells in Parkinson’s disease
Objective: We examined the methylation status of the DNA SNCA-intron1 at CD45+ blood cells in patients with sporadic Parkinson's disease (PD). Background: PD is a…An agent-based model replicates the pathogenic spread of alpha-synuclein in mice
Objective: To investigate the ability of a susceptible-infected-removed (SIR) agent-based model to predict the pathogenic spread of alpha-synuclein fibrils after injection in mice. Background: Parkinson’s…Electrochemical skin conductance as a marker of autonomic failure in patients with Multiple System Atrophy
Objective: We investigated the interest of a quick and non-invasive assessment of sweating as a marker of autonomic failure (AF) in Multiple System Atrohpy (MSA).…Discrimination of alpha-synuclein strains and sub-strains in Synucleinopathies
Objective: To differentiate and characterize alpha-synuclein strains and sub-strains associated with synucleinopathies. Background: Synucleinopathies are a diverse group of neurodegenerative diseases characterized by misfolding aggregation…Red blood cells alpha-synuclein heteroaggregates in the differential diagnosis of Lewy body dementias, Alzheimer’s disease and healthy controls
Objective: To investigate the diagnostic value of red blood cells (RBC) levels of total alpha-synuclein (α-syn), beta-amyloid (Aβ) 1-42, tau and its heteroaggregates in Lewy…Difference in distribution between alpha-synuclein oligomers and Lewy bodies in Parkinson’s disease brain
Objective: To examine the distribution of alpha-synuclein (αSYN) oligomers in Parkinson’s disease (PD) brains and compare the distribution of αSYN oligomers and Lewy bodies. Background:…Cardiac Safety of PBT434, an Inhibitor of Alpha-Synuclein Aggregation for the Treatment of Multiple System Atrophy (MSA)
Objective: Evaluate potential cardiac liability of PBT434 using concentration-response and outlier analyses of ECG and pharmacokinetic (PK) data from a Phase 1 study of PBT434…Cerebral microvascular injury provoked by alpha-synuclein preformed fibrils exacerbates cognitive dysfunction in Parkinson’s disease
Objective: The aim of this study was to investigate the role of microvascular pathology between abnormal αSyn aggregation and PD cognitive dysfunction. Background: Higher plasma…α-Synuclein propagation via olfactory pathway induces olfactory bulb atrophy and widespread glucose hypometabolism in a non-human primate model
Objective: We investigated how α-synuclein (α-Syn) pathology spreads from the olfactory bulb (OB) and how the pathology affects brain structure and activity. Background: Parkinson's disease…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 60
- Next Page »